Summit Therapeutics’ Phase 3 trial met the primary goal in lung cancer, showing significant PFS benefit with ivonescimab plus chemotherapy.
Summit Therapeutics’ Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint
Where Today's News Shapes Tomorrow
